<DOC>
	<DOCNO>NCT00008138</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug combine chemotherapy surgery may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy surgery treat patient stage III stage IV ovarian epithelial cancer , primary peritoneal cancer , fallopian tube cancer .</brief_summary>
	<brief_title>S0009 Combination Chemo Surgery Stage III Stage IV Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate overall survival progression-free survival patient stage III IV ovarian epithelial cancer , primary peritoneal cancer , fallopian tube cancer treat neoadjuvant paclitaxel carboplatin follow surgery adjuvant paclitaxel carboplatin . - Estimate percentage patient whose disease successfully cytoreduced less 1 cm diameter follow neoadjuvant chemotherapy . - Evaluate toxicity regimen patient . - Explore relationship tumor p53 expression , proliferation rate measure proliferate cell nuclear antigen apoptotic rate , human tumor clone assay result time debulking surgery progression-free survival overall survival patient treat regimen . OUTLINE : This multicenter study . Patients receive neoadjuvant therapy comprise paclitaxel IV 3 hour follow carboplatin IV 30-60 minute day 1 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Within 35 day receive third course chemotherapy , patient least 50 % reduction CA 125 undergo debulking surgery . Within 35 day undergo surgery , patient tumor reduction 1 cm receive adjuvant therapy comprise paclitaxel IV 3 hour follow carboplatin intraperitoneally ( IP ) day 1 paclitaxel IP day 8 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year , every 6 month 2 year , annually 5 year . PROJECTED ACCRUAL : A total 55 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage III IV ovarian epithelial cancer , primary peritoneal cancer , fallopian tube cancer Adenocarcinoma Large pelvic mass and/or bulky abdominal disease and/or malignant pleural effusion Pleural effusion stage IV ( parenchymal , liver , lung , distant metastasis allow ) No borderline lowmalignant potential tumor Optimal cytoreduction clinically deem unlikely CA 125 least 70 units/mL PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT great 2 time ULN Renal : Creatinine clearance least 50 mL/min Cardiovascular : No congestive heart failure cardiac arrhythmia No myocardial infarction angina within past 6 month Other : Not pregnant nursing Fertile patient must use effective contraception No severe gastrointestinal symptom ( i.e. , partial obstruction ) and/or gastrointestinal bleeding No grade 2 great sensory neuropathy No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission No active uncontrolled infection PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy cancer Chemotherapy : No prior chemotherapy cancer Endocrine therapy : Not specify Radiotherapy : No prior pelvic radiation cancer Surgery : See Disease Characteristics Prior exploratory laparotomy allow provided aggressive tumor debulking procedure perform ( e.g. , bilateral salpingooophorectomy/total abdominal hysterectomy omentectomy ) Prior salpingooophorectomy and/or partial omentectomy allow Other : No concurrent anticancer therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>